ATAI
Price
$2.45
Change
-$0.03 (-1.21%)
Updated
Jun 6, 01:21 PM (EDT)
Capitalization
494.83M
73 days until earnings call
CRSP
Price
$41.43
Change
+$2.86 (+7.42%)
Updated
Jun 6, 02:39 PM (EDT)
Capitalization
3.33B
66 days until earnings call
Interact to see
Advertisement

ATAI vs CRSP

Header iconATAI vs CRSP Comparison
Open Charts ATAI vs CRSPBanner chart's image
ATAI Life Sciences
Price$2.45
Change-$0.03 (-1.21%)
Volume$4K
Capitalization494.83M
CRISPR Therapeutics AG
Price$41.43
Change+$2.86 (+7.42%)
Volume$983
Capitalization3.33B
ATAI vs CRSP Comparison Chart
Loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATAI vs. CRSP commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Buy and CRSP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ATAI: $2.48 vs. CRSP: $38.57)
Brand notoriety: ATAI and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 100% vs. CRSP: 120%
Market capitalization -- ATAI: $494.83M vs. CRSP: $3.33B
ATAI [@Biotechnology] is valued at $494.83M. CRSP’s [@Biotechnology] market capitalization is $3.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, ATAI is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 7 TA indicator(s) are bullish while CRSP’s TA Score has 7 bullish TA indicator(s).

  • ATAI’s TA Score: 7 bullish, 3 bearish.
  • CRSP’s TA Score: 7 bullish, 1 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than ATAI.

Price Growth

ATAI (@Biotechnology) experienced а +6.90% price change this week, while CRSP (@Biotechnology) price change was +4.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.36%. For the same industry, the average monthly price growth was +17.11%, and the average quarterly price growth was +3.22%.

Reported Earning Dates

ATAI is expected to report earnings on Aug 18, 2025.

CRSP is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+11.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.33B) has a higher market cap than ATAI($495M). ATAI YTD gains are higher at: 86.466 vs. CRSP (-2.007). ATAI has higher annual earnings (EBITDA): -124.33M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. ATAI (85.9M). ATAI has less debt than CRSP: ATAI (23.8M) vs CRSP (219M). CRSP has higher revenues than ATAI: CRSP (35M) vs ATAI (331K).
ATAICRSPATAI / CRSP
Capitalization495M3.33B15%
EBITDA-124.33M-455.24M27%
Gain YTD86.466-2.007-4,308%
P/E RatioN/AN/A-
Revenue331K35M1%
Total Cash85.9M1.86B5%
Total Debt23.8M219M11%
FUNDAMENTALS RATINGS
ATAI vs CRSP: Fundamental Ratings
ATAI
CRSP
OUTLOOK RATING
1..100
2811
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
9592
PRICE GROWTH RATING
1..100
3564
P/E GROWTH RATING
1..100
1478
SEASONALITY SCORE
1..100
7837

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (65) in the Biotechnology industry is in the same range as ATAI (67) in the Miscellaneous Commercial Services industry. This means that CRSP’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Profit vs Risk Rating (94) in the Miscellaneous Commercial Services industry is in the same range as CRSP (100) in the Biotechnology industry. This means that ATAI’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (92) in the Biotechnology industry is in the same range as ATAI (95) in the Miscellaneous Commercial Services industry. This means that CRSP’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Price Growth Rating (35) in the Miscellaneous Commercial Services industry is in the same range as CRSP (64) in the Biotechnology industry. This means that ATAI’s stock grew similarly to CRSP’s over the last 12 months.

ATAI's P/E Growth Rating (14) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for CRSP (78) in the Biotechnology industry. This means that ATAI’s stock grew somewhat faster than CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATAICRSP
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 8 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FVLAX20.03N/A
N/A
Fidelity Advisor Value Leaders A
BMCIX28.00N/A
N/A
BlackRock High Equity Income Instl
MSFJX19.21N/A
N/A
MFS Total Return R4
NEMRX21.71N/A
N/A
Neuberger Berman Emerg Mkts Eq R3
RUNTX23.75N/A
N/A
Russell Inv US Small Cap Equity M